• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • EXONDYS 51
    / Medison


    Active Ingredient
    Eteplirsen 50 mg/ml

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Concentrate for solution for infusion

    1 X 2 ml

    not in the basket chart

    Concentrate for solution for infusion

    1 X 10 ml

    not in the basket chart

    Related information


    Dosage

    The recommended dose is 30 milligrams per kilogram administered once weekly.
    Administration: Administered as a 35 to 60-minute intravenous infusion via an in-line 0.2 micron filter. Flush the line with 0.9% Sodium Chloride before and after infusion. Do not mix with other medicinal products or infuse through the same IV line.
    If a dose is missed, it may be administered as soon as possible after the scheduled time.
    Premedication: Application of a topical anesthetic cream to the infusion site prior to administration of may be considered.
    Preparation: Allow vials to warm to room temperature. Gently invert vials 2-3 times (do not shake). Dilute the withdrawn product in 0.9% Sodium Chloride Injection, USP, to make a total volume of 100-150 ml.


    Indications

    Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients


    Special Precautions

    Hypersensitivity Reactions: Hypersensitivity reactions, including bronchospasm, chest pain, cough, tachycardia, and urticaria, have occurred. If a reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting therapy.


    Side Effects

    Most common: Balance disorder, Vomiting, Contact dermatitis
    See prescribing information for full details.


    Drug interactions

    No clinical drug interaction studies have been conducted. The active substance is not expected to interact with CYP450 enzymes based on in vitro data.


    Pregnancy and Lactation

    Pregnancy: There are no human data on the use of the medicinal product in pregnant women.
    Lactation
    : There is no information regarding the presence of the drug in human milk, effects on the breastfed infant, or effects on milk production.


    Important notes

    Complete infusion of diluted solution within 8 hours of dilution. If immediate use is not possible, the diluted solution may be stored for up to 24 hours at 2ºC to 8ºC. Do not freeze.


    Manufacturer
    Sarepta Therapeutics, Inc.
    Licence holder

    סרגל נגישות

    CLOSE